RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nuo Therapeutics Stock

Nuo Therapeutics P/E 2025

Nuo Therapeutics P/E

-7.3

Ticker

AURX

ISIN

US67059V2097

WKN

A2AP5P

As of Mar 4, 2025, Nuo Therapeutics's P/E ratio was -7.3, a -61.44% change from the -18.93 P/E ratio recorded in the previous year.

The Nuo Therapeutics P/E history

Nuo Therapeutics Aktienanalyse

What does Nuo Therapeutics do?

Nuo Therapeutics Inc is a US-American company specializing in the development and marketing of medical products and therapies for wound healing. The company was originally founded in 2002 as Cytomedix and was renamed Nuo Therapeutics in 2016. The company's history stems from the discovery of growth factors produced by human platelets, which play an important role in wound healing. Research has shown that these growth factors can be used to expedite wound healing, making it a promising approach for the development of new medical therapies. Nuo Therapeutics aims to develop and bring innovative wound healing products and therapies to the market. The company specializes in three main areas: biosurgery, dermatology, and advanced wound care. In the biosurgery division, Nuo Therapeutics offers a range of medical products that can be used for hemostasis and wound care. This includes Nexagon® Gel, a wound treatment product based on the aforementioned growth factors, and SurgiWrapTM, a barrier membrane for the protection of surgically treated soft tissues. In the dermatology division, Nuo Therapeutics focuses on the development of therapeutic products for the treatment of skin conditions such as eczema, psoriasis, and acne. To this end, the company has entered into an agreement with a leading pharmaceutical company to develop the skincare product SECUAADTM. The advanced wound care division of Nuo Therapeutics focuses on the treatment of difficult, chronic wounds that do not heal. In this area, the company has acquired the rights to a unique technology called AurixTM, which is based on the use of growth factors from the patient's own blood. With AurixTM, Nuo Therapeutics aims to help patients with hard-to-heal wounds heal their wounds faster and more safely. The business model of Nuo Therapeutics is based on the development and commercialization of innovative medical products and therapies. The company relies on partnerships with other companies in the pharmaceutical and medical industries to support the development and marketing of its products. Nuo Therapeutics has experienced strong growth in recent years and has established itself as a key player in the market for medical wound healing products. With its innovative products and therapies, the company is well positioned to continue growing in the future and make a significant contribution to improving medical care for patients worldwide. Nuo Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Nuo Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Nuo Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Nuo Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Nuo Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Nuo Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Nuo Therapeutics stock

What is the price-to-earnings ratio of Nuo Therapeutics?

The price-earnings ratio of Nuo Therapeutics is currently -7.3.

How has the price-earnings ratio of Nuo Therapeutics changed compared to last year?

The price-to-earnings ratio of Nuo Therapeutics has increased by -61.44% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Nuo Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Nuo Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Nuo Therapeutics affect the company?

An increase in the price-earnings ratio of Nuo Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Nuo Therapeutics affect the company?

A decrease in the price-earnings ratio of Nuo Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Nuo Therapeutics?

Some factors that influence the price-earnings ratio of Nuo Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Nuo Therapeutics pay?

Over the past 12 months, Nuo Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nuo Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nuo Therapeutics?

The current dividend yield of Nuo Therapeutics is .

When does Nuo Therapeutics pay dividends?

Nuo Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nuo Therapeutics?

Nuo Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nuo Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nuo Therapeutics located?

Nuo Therapeutics is assigned to the '-' sector.

Wann musste ich die Aktien von Nuo Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nuo Therapeutics from 3/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/4/2025.

When did Nuo Therapeutics pay the last dividend?

The last dividend was paid out on 3/4/2025.

What was the dividend of Nuo Therapeutics in the year 2024?

In the year 2024, Nuo Therapeutics distributed 0 USD as dividends.

In which currency does Nuo Therapeutics pay out the dividend?

The dividends of Nuo Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nuo Therapeutics

Our stock analysis for Nuo Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nuo Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.